Instruction of myeloid cells by the tumor microenvironment Open questions on the dynamics and plasticity of different tumor-associated myeloid cell populations

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1135-1145

  Schouppe, Elio ^a,b   Baetselier, Patrick De ^a,b   Van Ginderachter, Jo A ^a,b   Sarukhan, Adelaida ^a,b,c  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c INSERM   (France)

Author keywords

ER stress; Exosomes; Hypoxia; Myeloid cell plasticity; Myeloid cells; Myeloid derived suppressor cells; Tumor associated dendritic cells; Tumor associated macrophages; Tumorassociated neutrophils

Indexed keywords

BONE MARROW CELL; CELL DIFFERENTIATION; CELL EXPANSION; CELL FUNCTION; CELL HETEROGENEITY; CELL MATURATION; CELL TRANSFORMATION; DYNAMICS; ENDOPLASMIC RETICULUM STRESS; EXOSOME; HUMAN; HYPOXIA; IMMUNE RESPONSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PLASTICITY; POLARIZATION; PRIORITY JOURNAL; REVIEW; TUMOR ASSOCIATED DENDRITIC CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ASSOCIATED NEUTROPHIL; TUMOR MICROENVIRONMENT;

EID: 84876186488     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21566     Document Type: Review

References (118)

1. Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012; 72:2473-80; PMID:22414581; http://dx.doi. org/10.1158/0008-5472.CAN-12-0122.
2. Mantovani A, Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010; 22:231-7; PMID:20144856; http:// dx.doi.org/10.1016/j.coi.2010.01.009.
3. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011; 21:139-46; PMID:21251983; http://dx.doi. org/10.1016/j.semcancer.2011.01.002.
4. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011; 11:702-11; PMID:21941296; http://dx.doi.org/10.1038/nri3064.
5. Bingle L, Brown NJ, Lewis CE. The role of tumourassociated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196:254-65; PMID:11857487; http://dx.doi. org/10.1002/path.1027.
6. Laoui D, Van Overmeire E, Movahedi K, Van den Bossche J, Schouppe E, Mommer C, et al. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology 2011; 216:1192-202; PMID:21803441; http://dx.doi.org/10.1016/j. imbio.2011.06.007.
7. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11:723-37; PMID:21997792; http://dx.doi. org/10.1038/nri3073.
8. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117:1155-66; PMID:17476345; http:// dx.doi.org/10.1172/JCI31422.
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi. org/10.1126/science.1129139.
10. Kurahara H, Shinchi H, Mataki Y, Maemura K, Noma H, Kubo F, et al. Significance of M2-polarized tumorassociated macrophage in pancreatic cancer. J Surg Res 2011; 167:e211-9; PMID:19765725; http://dx.doi. org/10.1016/j.jss.2009.05.026.
11. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangé G, Van den Bossche J, et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010; 70:5728-39; PMID:20570887; http://dx.doi.org/10.1158/0008-5472.CAN-09-4672.
12. Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, et al. Nanobody-based targeting of the Macrophage Mannose Receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res 2012; (E-pub ahead of print); PMID:22719068; http://dx.doi.org/10.1158/0008-5472.CAN-11-2994.
13. Coffelt SB, Tal AO, Scholz A, De Palma M, Patel S, Urbich C, et al. Angiopoietin-2 regulates gene expression in TIE2-expressing monocytes and augments their inherent proangiogenic functions. Cancer Res 2010; 70:5270-80; PMID:20530679; http://dx.doi. org/10.1158/0008-5472.CAN-10-0012.
14. De Palma M, Venneri MA, Galli R, Sergi Sergi L, Politi LS, Sampaolesi M, et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8:211-26; PMID:16169466; http://dx.doi.org/10.1016/j. ccr.2005.08.002.
15. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9:162-74; PMID:19197294; http:// dx.doi.org/10.1038/nri2506.
16. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182:4499-506; PMID:19342621; http://dx.doi.org/10.4049/jimmunol.0802740.
17. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111:4233-44; PMID:18272812; http://dx.doi.org/10.1182/blood-2007-07-099226.
18. Youn J-I, Nagaraj S, Collazo M, Gabrilovich DI. Subsets of myeloid-derived suppressor cells in tumorbearing mice. J Immunol 2008; 181:5791-802; PMID:18832739.
19. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012; 61:255-63; PMID:22120756; http://dx.doi. org/10.1007/s00262-011-1161-9.
20. Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur J Immunol 2010; 40:22-35; PMID:19941314; http://dx.doi. org/10.1002/eji.200939903.
21. Lesokhin AM, Hohl TM, Kitano S, Cortez C, Hirschhorn-Cymerman D, Avogadri F, et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72:876-86; PMID:22174368; http://dx.doi. org/10.1158/0008-5472.CAN-11-1792.
22. Solito S, Bronte V, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 2011; 90:31-6; PMID:21486906; http://dx.doi.org/10.1189/jlb.0111021.
23. Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13:828-35; PMID:17603493; http:// dx.doi.org/10.1038/nm1609.
24. Guilliams M, Henri S, Tamoutounour S, Ardouin L, Schwartz-Cornil I, Dalod M, et al. From skin dendritic cells to a simplified classification of human and mouse dendritic cell subsets. Eur J Immunol 2010; 40:2089-94; PMID:20853491; http://dx.doi.org/10.1002/ eji.201040498.
25. Joffre O, Nolte MA, Spörri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev 2009; 227:234-47; PMID:19120488; http://dx.doi. org/10.1111/j.1600-065X.2008.00718.x.
26. Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol 2011; 23:146-52; PMID:20970973; http://dx.doi.org/10.1016/j.coi.2010.09.008.
27. Engelhardt JJ, Boldajipour B, Beemiller P, Pandurangi P, Sorensen C, Werb Z, et al. Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 2012; 21:402-17; PMID:22439936; http://dx.doi.org/10.1016/j.ccr.2012.01.008.
28. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9:562-7; PMID:12704383; http://dx.doi. org/10.1038/nm863.
29. Liu Q, Zhang C, Sun A, Zheng Y, Wang L, Cao X. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol 2009; 182:6207-16; PMID:19414774; http://dx.doi.org/10.4049/jimmunol.0803926.
30. Kuang D-M, Zhao Q, Xu J, Yun JP, Wu C, Zheng L. Tumor-educated tolerogenic dendritic cells induce CD3epsilon down-regulation and apoptosis of T cells through oxygen-dependent pathways. J Immunol 2008; 181:3089-98; PMID:18713979.
31. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA 3rd, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 2008; 105:17073-8; PMID:18952840; http://dx.doi. org/10.1073/pnas.0806173105.
32. Fridman W-H, Galon J, Pagès F, Tartour E, Sautès- Fridman C, Kroemer G. Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 2011; 71:5601-5; PMID:21846822; http://dx.doi.org/10.1158/0008-5472.CAN-11-1316.
33. Hiraoka N, Yamazaki-Itoh R, Ino Y, Mizuguchi Y, Yamada T, Hirohashi S, et al. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 2011; 140:310-21; PMID:20955708; http://dx.doi.org/10.1053/j. gastro.2010.10.009.
34. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:22351930; http://dx.doi.org/10.1084/ jem.20111413.
35. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol 2010; 31:318-24; PMID:20620114; http://dx.doi.org/10.1016/j. it.2010.05.006.
36. Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res 2011; 71:2411-6; PMID:21427354; http://dx.doi. org/10.1158/0008-5472.CAN-10-2583.
37. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009; 16:183-94; PMID:19732719; http://dx.doi.org/10.1016/j.ccr.2009.06.017.
38. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12:253-68; PMID:22437938; http://dx.doi.org/10.1038/nri3175.
39. Sica A, Porta C, Morlacchi S, et al. Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs). Cancer Microenviron 2012; 5:133-49; PMID:21948460; http://dx.doi.org/10.1007/s12307-011-0091-6.
40. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-31; PMID:18633355; http://dx.doi.org/10.1038/nrc2444.
41. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J 2002; 16:1151-62; PMID:12153983; http://dx.doi.org/10.1096/fj.01-0944rev.
42. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13:206-20; PMID:18328425; http://dx.doi. org/10.1016/j.ccr.2008.01.034.
43. Alfaro C, Suárez N, Martínez-Forero I, Palazón A, Rouzaut A, Solano S, et al. Carcinoma-derived interleukin- 8 disorients dendritic cell migration without impairing T-cell stimulation. PLoS One 2011; 6:e17922; PMID:21423807; http://dx.doi.org/10.1371/journal. pone.0017922.
44. Hannah S, Mecklenburgh K, Rahman I, Bellingan GJ, Greening A, Haslett C, et al. Hypoxia prolongs neutrophil survival in vitro. FEBS Lett 1995; 372:233-7; PMID:7556675; http://dx.doi.org/10.1016/0014-5793(95)00986-J.
45. Fang H-Y, Hughes R, Murdoch C, Coffelt SB, Biswas SK, Harris AL, et al. Hypoxia-inducible factors 1 and 2 are important transcriptional effectors in primary macrophages experiencing hypoxia. Blood 2009; 114:844-59; PMID:19454749; http://dx.doi.org/10.1182/ blood-2008-12-195941.
46. Burke B, Giannoudis A, Corke KP, Gill D, Wells M, Ziegler-Heitbrock L, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 2003; 163:1233-43; PMID:14507633; http://dx.doi.org/10.1016/S0002-9440(10)63483-9.
47. Takeda N, O'Dea EL, Doedens A, Kim JW, Weidemann A, Stockmann C, et al. Differential activation and antagonistic function of HIF-alpha isoforms in macrophages are essential for NO homeostasis. Genes Dev 2010; 24:491-501; PMID:20194441; http://dx.doi. org/10.1101/gad.1881410.
48. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF- 2alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 2000; 157:411-21; PMID:10934146; http://dx.doi.org/10.1016/ S0002-9440(10)64554-3.
49. Imtiyaz HZ, Williams EP, Hickey MM, Patel SA, Durham AC, Yuan LJ, et al. Hypoxia-inducible factor 2alpha regulates macrophage function in mouse models of acute and tumor inflammation. J Clin Invest 2010; 120:2699-714; PMID:20644254; http://dx.doi. org/10.1172/JCI39506.
50. Boelte KC, Gordy LE, Joyce S, Thompson MA, Yang L, Lin PC. Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1. PLoS One 2011; 6:e18534; PMID:21494556; http://dx.doi. org/10.1371/journal.pone.0018534.
51. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF-1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207:2439-53; PMID:20876310; http://dx.doi.org/10.1084/ jem.20100587.
52. Mancino A, Schioppa T, Larghi P, Pasqualini F, Nebuloni M, Chen IH, et al. Divergent effects of hypoxia on dendritic cell functions. Blood 2008; 112:3723-34; PMID:18694997; http://dx.doi. org/10.1182/blood-2008-02-142091.
53. Mahadevan NR, Zanetti M. Tumor stress inside out: cell-extrinsic effects of the unfolded protein response in tumor cells modulate the immunological landscape of the tumor microenvironment. J Immunol 2011; 187:4403-9; PMID:22013206; http://dx.doi. org/10.4049/jimmunol.1101531.
54. Jamora C, Dennert G, Lee AS. Inhibition of tumor progression by suppression of stress protein GRP78/ BiP induction in fibrosarcoma B/C10ME. Proc Natl Acad Sci U S A 1996; 93:7690-4; PMID:8755537; http://dx.doi.org/10.1073/pnas.93.15.7690.
55. Mahadevan NR, Rodvold J, Sepulveda H, Rossi S, Drew AF, Zanetti M. Transmission of endoplasmic reticulum stress and pro-inflammation from tumor cells to myeloid cells. Proc Natl Acad Sci U S A 2011; 108:6561-6; PMID:21464300; http://dx.doi. org/10.1073/pnas.1008942108.
56. Zhang K, Shen X, Wu J, Sakaki K, Saunders T, Rutkowski DT, et al. Endoplasmic reticulum stress activates cleavage of CREBH to induce a systemic inflammatory response. Cell 2006; 124:587-99; PMID:16469704; http://dx.doi.org/10.1016/j. cell.2005.11.040.
57. Théry C, Boussac M, Véron P, Ricciardi-Castagnoli P, Raposo G, Garin J, et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001; 166:7309-18; PMID:11390481.
58. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res 2011; 17:959-64; PMID:21224375; http://dx.doi.org/10.1158/1078-0432.CCR-10-1489.
59. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 2011; 33:441-54; PMID:21688197; http://dx.doi. org/10.1007/s00281-010-0234-8.
60. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res 2006; 66:9290-8; PMID:16982774; http://dx.doi.org/10.1158/0008-5472.CAN-06-1819.
61. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 2007; 178:6867-75; PMID:17513735.
62. Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009; 124:2621-33; PMID:19235923; http://dx.doi.org/10.1002/ ijc.24249.
63. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3- dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest 2010; 120:457-71; PMID:20093776.
64. Takizawa T, Nishinarita S, Kitamura N, Hayakawa J, Kang H, Tomita Y, et al. Interaction of the cellbinding domain of fibronectin with VLA-5 integrin induces monokine production in cultured human monocytes. Clin Exp Immunol 1995; 101:376-82; PMID:7648723.
65. Poutsiaka DD, Schroder EW, Taylor DD, Levy EM, Black PH. Membrane vesicles shed by murine melanoma cells selectively inhibit the expression of Ia antigen by macrophages. J Immunol 1985; 134:138-44; PMID:2578042.
66. Zeelenberg IS, Ostrowski M, Krumeich S, Bobrie A, Jancic C, Boissonnas A, et al. Targeting tumor antigens to secreted membrane vesicles in vivo induces efficient antitumor immune responses. Cancer Res 2008; 68:1228-35; PMID:18281500; http://dx.doi. org/10.1158/0008-5472.CAN-07-3163.
67. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 2008; 205:2235-49; PMID:18809714; http://dx.doi. org/10.1084/jem.20080132.
68. Shurin GV, Ouellette CE, Shurin MR. Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother 2012; 61:223-30; PMID:22065047; http://dx.doi.org/10.1007/s00262-011-1138-8.
69. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012; 188:21-8; PMID:22187483; http://dx.doi.org/10.4049/jimmunol. 1101029.
70. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, et al. Non-small cell lung cancer cyclooxygenase- 2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998; 58:1208-16; PMID:9515807.
71. Rodríguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, et al. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 2005; 202:931-9; PMID:16186186; http://dx.doi.org/10.1084/jem.20050715.
72. Flavell RA, Sanjabi S, Wrzesinski SH, Licona- Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10:554-67; PMID:20616810; http://dx.doi. org/10.1038/nri2808.
73. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res 2011; 51:170-82; PMID:22139852; http://dx.doi. org/10.1007/s12026-011-8262-6.
74. Liu YY, Sun LC, Wei JJ, Li D, Yuan Y, Yan B, et al. Tumor cell-released TLR4 ligands stimulate Gr-1+CD11b+F4/80+ cells to induce apoptosis of activated T cells. J Immunol 2010; 185:2773-82; PMID:20675592; http://dx.doi.org/10.4049/jimmunol. 1000772.
75. Coffelt SB, Chen Y-Y, Muthana M, Welford AF, Tal AO, Scholz A, et al. Angiopoietin 2 stimulates TIE2- expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J Immunol 2011; 186:4183-90; PMID:21368233; http://dx.doi. org/10.4049/jimmunol.1002802.
76. Pucci F, Venneri MA, Biziato D, Nonis A, Moi D, Sica A, et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood "resident" monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009; 114:901-14; PMID:19383967; http://dx.doi.org/10.1182/blood-2009-01-200931.
77. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, Kolhatkar N, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009; 16:91-102; PMID:19647220; http://dx.doi. org/10.1016/j.ccr.2009.06.018.
78. Gocheva V, Wang H-W, Gadea BB, Shree T, Hunter KE, Garfall AL, et al. IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. Genes Dev 2010; 24:241-55; PMID:20080943; http://dx.doi.org/10.1101/ gad.1874010.
79. Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE, et al. Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell 2011; 19:441-55; PMID:21481787; http://dx.doi.org/10.1016/j.ccr.2011.03.002.
80. Mazzieri R, Pucci F, Moi D, Zonari E, Ranghetti A, Berti A, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19:512-26; PMID:21481792; http://dx.doi.org/10.1016/j.ccr.2011.02.005.
81. Borrello MG, Alberti L, Fischer A, Degl'innocenti D, Ferrario C, Gariboldi M, et al. Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc Natl Acad Sci U S A 2005; 102:14825-30; PMID:16203990; http://dx.doi. org/10.1073/pnas.0503039102.
82. Viola A, Sarukhan A, Bronte V, Molon B. The pros and cons of chemokines in tumor immunology. Trends Immunol 2012; E-pub ahead of print
83. Bottazzi B, Polentarutti N, Acero R, Balsari A, Boraschi D, Ghezzi P, et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983; 220:210-2; PMID:6828888; http://dx.doi. org/10.1126/science.6828888.
84. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6:3282-9; PMID:10955814.
85. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011; 475:222-5; PMID:21654748; http:// dx.doi.org/10.1038/nature10138.
86. Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 2008; 111:5457-66; PMID:18375791; http://dx.doi.org/10.1182/blood- 2008-01-136895.
87. Pahler JC, Tazzyman S, Erez N, Chen YY, Murdoch C, Nozawa H, et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008; 10:329-40; PMID:18392134.
88. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell 2012; 21:488-503; PMID:22516258; http://dx.doi. org/10.1016/j.ccr.2012.02.017.
89. Obermajer N, Muthuswamy R, Odunsi K, Edwards RP, Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res 2011; 71:7463-70; PMID:22025564; http://dx.doi.org/10.1158/0008-5472.CAN-11-2449.
90. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med 2011; 208:1949-62; PMID:21930770; http://dx.doi. org/10.1084/jem.20101956.
91. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA. CD99 plays a major role in the migration of monocytes through endothelial junctions. Nat Immunol 2002; 3:143-50; PMID:11812991; http:// dx.doi.org/10.1038/ni749.
92. Ueha S, Shand FHW, Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol 2011; 11:783-8; PMID:21406269; http://dx.doi.org/10.1016/j. intimp.2011.03.003.
93. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70:3526-36; PMID:20406969; http://dx.doi. org/10.1158/0008-5472.CAN-09-3278.
94. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332:1284-8; PMID:21566158; http://dx.doi.org/10.1126/science. 1204351.
95. Aziz A, Soucie E, Sarrazin S, Sieweke MH. MafB/c- Maf deficiency enables self-renewal of differentiated functional macrophages. Science 2009; 326:867-71; PMID:19892988; http://dx.doi.org/10.1126/science. 1176056.
96. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006; 66:605-12; PMID:16423985; http://dx.doi. org/10.1158/0008-5472.CAN-05-4005.
97. Kuang D-M, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood 2007; 110:587-95; PMID:17395778; http://dx.doi.org/10.1182/ blood-2007-01-068031.
98. Wang B, Li Q, Qin L, Zhao S, Wang J, Chen X. Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice. BMC Immunol 2011; 12:43; PMID:21813021; http://dx.doi.org/10.1186/1471-2172-12-43.
99. Egeblad M, Ewald AJ, Askautrud HA, Truitt ML, Welm BE, Bainbridge E, et al. Visualizing stromal cell dynamics in different tumor microenvironments by spinning disk confocal microscopy. Dis Model Mech 2008; 1:155-67, discussion 165; PMID:19048079; http://dx.doi.org/10.1242/dmm.000596.
100. Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors. J Immunol 2010; 184:702-12; PMID:20018620; http:// dx.doi.org/10.4049/jimmunol.0902360.
101. Matsumoto S, Yasui H, Mitchell JB, Krishna MC. Imaging cycling tumor hypoxia. Cancer Res 2010; 70:10019-23; PMID:21159626; http://dx.doi. org/10.1158/0008-5472.CAN-10-2821.
102. Liu Y, Van Ginderachter JA, Brys L, De Baetselier P, Raes G, Geldhof AB. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol 2003; 170:5064-74; PMID:12734351.
103. Van Ginderachter JA, Meerschaut S, Liu Y, Brys L, De Groeve K, Hassanzadeh Ghassabeh G, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 2006; 108:525-35; PMID:16527895; http:// dx.doi.org/10.1182/blood-2005-09-3777.
104. Banerjee S, Lin C-FL, Skinner KA, Schiffhauer LM, Peacock J, Hicks DG, et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res 2011; 71:318-27; PMID:21224361; http://dx.doi. org/10.1158/0008-5472.CAN-10-1778.
105. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012; 188:1592-9; PMID:22231700; http://dx.doi. org/10.4049/jimmunol.1101304.
106. Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, Hodohara K, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas. J Biol Chem 2011; 286:22403-13; PMID:21515679; http://dx.doi.org/10.1074/jbc. M110.215301.
107. Allavena P, Piemonti L, Longoni D, Bernasconi S, Stoppacciaro A, Ruco L, et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998; 28:359-69; PMID:9485215; http://dx.doi.org/10.1002/ (SICI)1521-4141(199801)28:01
108. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998; 92:4778-91; PMID:9845545.
109. Diao J, Mikhailova A, Tang M, Gu H, Zhao J, Cattral MS. Immunostimulatory conventional dendritic cells evolve into regulatory macrophage-like cells. Blood 2012; 119:4919-27; PMID:22490680; http://dx.doi. org/10.1182/blood-2011-11-392894.
110. Linde N, Lederle W, Depner S, van Rooijen N, Gutschalk CM, Mueller MM. Vascular endothelial growth factor-induced skin carcinogenesis depends on recruitment and alternative activation of macrophages. J Pathol 2012; 227:17-28; PMID:22262122; http:// dx.doi.org/10.1002/path.3989.
111. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, et al. Abrogation of TGF β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13:23-35; PMID:18167337; http://dx.doi.org/10.1016/j. ccr.2007.12.004.
112. Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 2006; 72:1622-31; PMID:16846592; http://dx.doi.org/10.1016/j.bcp.2006.05.017.
113. Markiewski MM, Lambris JD. Unwelcome complement. Cancer Res 2009; 69:6367-70; PMID:19654288; http://dx.doi.org/10.1158/0008-5472.CAN-09-1918.
114. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 2010; 115:1461-71; PMID:20008303; http://dx.doi.org/10.1182/blood- 2009-08-237412.
115. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10:181-93; PMID:20168319; http:// dx.doi.org/10.1038/nrc2809.
116. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al. Origins of tumorassociated macrophages and neutrophils. Proc Natl Acad Sci U S A 2012; 109:2491-6; PMID:22308361; http://dx.doi.org/10.1073/pnas.1113744109
117. Hart KM, Bak SP, Alonso A, Berwin B. Phenotypic and functional delineation of murine CX(3)CR1 monocyte- derived cells in ovarian cancer. Neoplasia 2009; 11:564-73, 1, 573; PMID:19484145.
118. Izhak L, Wildbaum G, Jung S, Stein A, Shaked Y, Karin N. Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis. PLoS One 2012; 7:e28305; PMID:22279523; http:// dx.doi.org/10.1371/journal.pone.0028305.